Loading stock data…
NUVB
$4.49+0.04 (+0.90%)
Market ClosedLast close May 1
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvation Bio Inc. in the Healthcare sector is trading at $4.49. The stock is currently 54% below its 52-week high of $9.75, remaining 9.3% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why NUVB maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.49
Potential Upside
5%
Whystock Fair Value$4.71
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ n...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.49%
Volume
Today's trading volume
2.64M
Recent News
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look At Nuvation Bio’s Valuation After Recent Share Price Swings
What Nuvation Bio’s recent trading performance suggests Nuvation Bio (NUVB) has caught investor attention after a sharp share price swing, with the stock showing a 0.2% move in the latest session and contrasting results over the past month and the past 3 months. See our latest analysis for Nuvation Bio. That recent 17.7% 30 day share price return contrasts with a 40.33% decline year to date. At the same time, the 1 year total shareholder return of 146.15% and 3 year total shareholder return...
Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year
Nuvation Bio, Inc. (NYSE:NUVB) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price more than doubled from a year ago, up 156.7%, while it registered a 40.79% increase year-to-date. On April 16, Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio with a price target of […]
Are Options Traders Betting on a Big Move in Nuvation Bio Stock?
Investors need to pay close attention to NUVB stock based on the movements in the options market lately.